CNS Pharma

Never miss an update! Subscribe for $CNSP alerts here: bit.ly/3qrwDZk #Oncology #Neurology #BolsteredTeam

We announced a new corporate strategy focused on building a high-value neurology and oncology pipeline, driven by a newly formed executive team and a disciplined, data-driven approach to identifying and advancing differentiated therapeutic assets. 🔗: bit.ly/4bGRsbp

An article titled “CNS Pharmaceuticals Wipes Pipeline Clean in Strategic Pivot to Fresh Neurology, Oncology Targets” was recently published by Fierce Biotech, highlighting our strategic decision to refocus our pipeline and advance new opportunities. 🔗: bit.ly/4bDSRQQ

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline bit.ly/4bGRsbp $CNSP #oncology #neurology #BolsteredTeam

As we close our Welcome to the Team series, we’re pleased to highlight the experienced leadership now in place. These appointments strengthen our ability to execute with discipline and advance our strategy with purpose. Learn more about our team here: bit.ly/4beORGn

Please welcome Dylan Wenke as Chief Business Officer! He brings extensive experience in corporate development, strategic partnerships and value-driving transactions. His background will support our focus on disciplined growth and long-term value creation. bit.ly/4beORGn

Rounding out the new leadership team, we’re pleased to welcome Lynne Kelley as Chief Medical Officer! Dr. Kelley brings 20+ years of global leadership in oncology clinical development and regulatory strategy, with experience leading Phase 1–3 programs. bit.ly/4beORGn

Next, welcome Eric Faulkner as Chief Technology Officer! He brings ~30 years translating complex science into scalable development & manufacturing programs. His leadership across CMC, technical operations and global regulatory execution will be essential. bit.ly/4beORGn

Welcome Steven O’Loughlin as Chief Financial Officer! He brings more than 15 years of financial leadership and capital markets experience. His expertise in finance, investor relations, strategic transactions and capital discipline will be instrumental. bit.ly/4beORGn

We’re pleased to introduce our Welcome to the Team series, highlighting the experienced leaders joining our executive team. We look forward to introducing each new member and sharing how their experience will help shape the next chapter of $CNSP. bit.ly/4beORGn

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team bit.ly/4ujdSrE $CNSP #BiotechExecutive #BolsteredTeam

Stay informed on CNS Pharma. From corporate updates to regulatory filings - get the information that matters delivered straight to you. 📩 Subscribe for updates: bit.ly/3XqjO2v $CNSP #Oncology

#DidYouSee: We bolstered our management team as part of our ongoing strategic transformation. The strengthened leadership team brings deep expertise to support the Company’s next phase of growth and value creation. Learn more here: bit.ly/4aVjX5K $CNSP #Oncology

Prevention starts with awareness and innovation. This #NationalCancerPreventionMonth, CNS Pharma continues to advance research focused on addressing unmet needs in aggressive cancers. $CNSP #Oncology

Rami Levin, emphasized that these leadership appointments are expected to be transformational, strengthening the Company’s ability to execute with discipline, engage stakeholders with credibility, and advance both current and future programs with purpose. bit.ly/4aVjX5K

CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company’s Recently Initiated Strategic Transformation bit.ly/4aVjX5K $CNSP #CNS #Oncology #BiotechExecutives

A Letter from Our CEO! Our President & Chief Executive Officer shares an update on CNS Pharmaceuticals’ progress, priorities, and path forward as we continue advancing our mission. Read more here: bit.ly/3Z1yLt2 $CNSP #Oncology

Rami Levin, CEO, shared that with a disciplined strategy and clear focus, CNS Pharmaceuticals is strengthening execution, prioritizing transparency, and positioning the Company for long-term value creation for patients and shareholders. bit.ly/3Z1yLt2 $CNSP #Oncology

CNS Pharmaceuticals Issues Letter to Shareholder bit.ly/3Z1yLt2 $CNSP #Oncology

The best way to get timely updates on our latest developments is by subscribing to email alerts for new press releases, events, and filings. Sign up here: bit.ly/3zD73t5 $CNSP #GlioblastomaMultiforme #GBM #Oncology